Tuesday 16 August 2011
AVI BioPharma - News Release
AVI BioPharma - News Release: "AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced that it has initiated dosing in a Phase 2 study of eteplirsen, the Company's lead exon-skipping therapeutic candidate for the treatment of Duchenne muscular dystrophy (DMD)"
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment